This review provides an overview of the biochemistry, pharmacology, and clinical suitability of various LMWHs and emerging anticoagulants for the management of venous thromboembolism.
The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants Andrew D Blann, Chee W KhooUniversity Department of Medicine, City Hospital, Birmingham, UKAbstract: As the risk factors for thrombosis are becoming better understood, so is the need for anticoagulation. The inherent difficulties with warfarin are such that a low-molecular-weight heparin (LMWH) is often the key therapeutic. However, there are several different species of LMWH available to the practitioner, which leads to the need for an objective guide. New agents are coming onto the marketplace, and these may supersede both warfarin and the heparins. The current report will review the biochemistry and pharmacology of different LWMHs and identify which are more suitable for the different presentations of venous thromboembolism. It will conclude with a brief synopsis of new agents which may supersede warfarin and heparin.Keywords: thrombosis, warfarin, heparin, anticoagulation
Andrew Andrew Blann (Tue,) studied this question.